Mihran Shirinian, MD
Basic profileMihran Shirinian is an Oncology physician affiliated with Adventist Health Glendale. OpenAlex indexes 17 publications with 1,042 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")
Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year20251 paymentResearch$44,200
- Caris MPIProgram year20251 paymentResearch$26,000
- AstraZenecaProgram year20251 paymentResearch$16,500
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.5%PD-1 inhibitor28.9%Pembrolizumab100%Keytruda1%Part D + Part B≥21 patientsPlatinum-based Drug23.7%Oxaliplatin98%Carboplatin2%Part B, office-administered≥17 patients+ 16 more classes in this area
Metabolism & gastrointestinal
16.9%Serotonin-3 Receptor Antagonist16.6%Ondansetron hydrochloride99%Ondansetron Odt1%Part D + Part B≥81 patientsSubstance P/Neurokinin-1 Receptor Antagonist0.2%Aprepitant93%Emend7%Part D<11 patients+ 5 more classes in this area
Blood & clotting
11%Parenteral Iron Replacement9.2%Iron sucrose100%Part B, office-administered≥18 patientsErythropoiesis-stimulating Agent1.5%Epoetin alfa99%Procrit1%Part D + Part B<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Avo Artinyan, MD
Adventist Health Glendale
Natalie Seiser, MD
Adventist Health Glendale
Vahram Ornekian
Adventist Health Glendale
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”